Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: What is reality and what is fiction?

Annals of the Rheumatic Diseases

Volumn 66, Issue 6, 2007, Pages 709-711

  Schett, Georg ^a   Landewé, Robert ^b   Van Der Heijde, Désirée ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GROWTH DIFFERENTIATION FACTOR 5; INFLIXIMAB; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; ANKYLOSIS; ARTHRODESIS; BONE DESTRUCTION; BONE REMODELING; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; ENTERITIS; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOARTHRITIS; OSTEOCLAST; OSTEOPHYTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE REMODELING; HUMANS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249800645     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.071159     Document Type: Editorial

References (24)

1. Storm EE, Kingsley DM. Joint patterning defects caused by single and double mutations in members of the bone morphogenetic protein (BMP) family. Development 1996;122:3969-79.
2. Hartmann C, Tabin CJ. Wnt-14 plays a pivotal role in inducing synovial joint formation in the developing appendicular skeleton. Cell 2001;104:341-51.
3. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-51.
4. Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005;1:47-54.
5. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000;43:2523-30.
6. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, et al. Tumor necrosis factor a-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-92.
7. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
8. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
9. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516.
10. Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082-93.
11. Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum 2003;48:3442-51.
12. Miller JR. The Wnts. Genome Biol 2001;3:3001-11.
13. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751-64.
14. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
15. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594- 602.
16. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
17. Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
18. Boers M, Kostense PJ, Verhoeven AC, van der Linden S. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis Rheum 2001;44:2242-6.
19. Ostergaard M, Duer A, Nielsen H, Johansen JS, Narvestad E, Ejbjerg BJ, et al. Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment. Ann Rheum Dis 2005;64:1503-6.
20. Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, Poole RA, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis (AS). Arthritis Rheum, 2007. In press.
21. Davis J, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. A randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
22. Braun J, Landewé R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
23. van der Heijde D, Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-2.
24. van der Heijde DM, Landewé RB, Ory P, Vosse D, Zhou L, Tsuji W, et al. Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65(Suppl 11):81.